Gynecologic Cancer News

Even when accounting for histopathology, presentation stage and other covariates, distant recurrence of uterine cancer was more likely to occur in women who are not white, according to a presenter at the virtual ASCO Annual Meeting.

The FDA approved a combination of pembrolizumab and chemotherapy, with or without bevacizumab, for certain women with persistent, recurrent or metastatic cervical cancer.

Genomic testing has afforded today’s patient the advantage of knowing when they harbor a potentially dangerous genetic mutation, such as BRCA1 or BRCA2.

David A. Eagle, MD, will join New York Cancer & Blood Specialists on Oct. 15.

Even among insured patients, germline BRCA testing is underutilized in women with newly diagnosed ovarian cancer, according to a study presented at the virtual ASCO Annual Meeting.

The FDA granted priority review to cemiplimab-rwlc for treatment of certain women with advanced cervical cancer.

To advance health equity, it is time to normalize the collection of sexual orientation and gender identity (SOGI) data in clinical practice and in health services research.

Standard cancer care may fail to adequately address the needs of LGBTQ+ individuals, who face substantial disparities in access to screening, treatment and outcomes.

The FDA granted fast track designation to CT-0508 for treatment of patients with solid tumors that overexpress human epidermal growth factor receptor 2.

More than a third of patients with solid tumors showed evidence of antitumor response after treatment with ADP-A2M4CD8, according to data presented at the virtual ESMO Congress.